Immucell (ICCC) Profit After Tax (2010 - 2026)

Immucell (ICCC) has reported Profit After Tax for 17 consecutive years, with $1.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Profit After Tax rose 265.56% year-over-year to $1.8 million; the trailing twelve-month figure through Jun 2026 stood at -$652354.0 (down 137.03% YoY), and the FY2025 full-year result was -$1.0 million, up 51.78% from the prior year.
• Profit After Tax rose to $1.8 million in Q2 2026 per ICCC's latest filing, from -$2.8 million in the prior quarter.
• Across five years, Profit After Tax topped out at $1.8 million in Q2 2026 and bottomed at -$2.8 million in Q4 2025.
• Historically, Profit After Tax has averaged -$566494.3 across 5 years, with a median of -$684148.0 in 2022.
• The sharpest annual moves came in 2022 and 2025: Profit After Tax slumped 2349.8% in 2022, then jumped 430.46% in 2025.
• Over 5 years, Profit After Tax stood at -$1.7 million in 2022, then surged by 31.66% to -$1.1 million in 2023, then jumped by 145.14% to $514555.0 in 2024, then slumped by 653.71% to -$2.8 million in 2025, then surged by 164.39% to $1.8 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $1.8 million, -$2.8 million, and -$139748.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.